Drug intelligence / Profile preview

AMP-CpG + EBV gp350 + EBVpoly

Development stage: Preclinical
Lead developer: Elicio Therapeutics
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

AMP-CpG + EBV gp350 + EBVpoly (ELI-003) is an investigational protein subunit vaccine developed by Elicio Therapeutics to prevent or treat Epstein-Barr virus (EBV) infection and its associated conditions, including infectious mononucleosis, EBV-related cancers, and multiple sclerosis. The vaccine utilizes Elicio's proprietary Amphiphile (AMP) platform to deliver a lymph node-targeted adjuvant, AMP-CpG (a TLR9 agonist), alongside two key antigens: EBV gp350, which targets neutralizing antibodies and CD4+ T cells, and EBVpoly, a polyepitope protein containing 20 CD8+ T cell epitopes from both latent and lytic EBV antigens. This combination is designed to induce a comprehensive and durable immune response, encompassing both humoral and cellular (CD4+ and CD8+) immunity. Preclinical studies have demonstrated potent and durable immune responses maintained for over seven months.

Other names: AMP-CpG + EBV gp350 + EBVpoly vaccineElicio EBV vaccine

Targets

TLR9 (Toll-like receptor 9)gp350 (Epstein-Barr virus glycoprotein 350)HLA-EBV-pMHC (Human leukocyte antigen class I and class II molecules presenting Epstein-Barr virus polyepitope and gp350 peptides)

Beyond the preview

Go deeper on AMP-CpG + EBV gp350 + EBVpoly.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMP-CpG + EBV gp350 + EBVpoly.

Explore the full profile